Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

SEC Filings

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
Filing date Form Description View
Apr 17, 2020 DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

0001140361-20-009126.pdf
0001140361-20-009126.rtf
0001140361-20-009126.xls
View HTML
May 14, 2020 UPLOAD

UPLOAD

0000000000-20-004282.pdf
0000000000-20-004282.rtf
View HTML
Jul 21, 2020 S-1

Registration statement for face-amount certificate companies

0001140361-20-016469.pdf
0001140361-20-016469.rtf
0001140361-20-016469.xls
View HTML
Jul 21, 2020 CORRESP

CORRESP

0001140361-20-016470.pdf
0001140361-20-016470.rtf
0001140361-20-016470.xls
View HTML
Jul 30, 2020 S-1/A

Amended Registration statement for face-amount certificate companies

0001140361-20-016987.pdf
0001140361-20-016987.rtf
0001140361-20-016987.xls
View HTML
Aug 4, 2020 CORRESP

CORRESP

0001140361-20-017488.pdf
0001140361-20-017488.rtf
0001140361-20-017488.xls
View HTML
Aug 4, 2020 CORRESP

CORRESP

0001140361-20-017489.pdf
0001140361-20-017489.rtf
0001140361-20-017489.xls
View HTML
Aug 6, 2020 8-A12B

Registration of certain classes of securities 12(b) of the Securities Exchange Act

0001140361-20-017640.pdf
0001140361-20-017640.rtf
0001140361-20-017640.xls
View HTML
Aug 6, 2020 S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

0001140361-20-017721.pdf
0001140361-20-017721.rtf
0001140361-20-017721.xls
View HTML
Aug 6, 2020 3

Initial filing by director officer or owner of more than ten percent.

0001140361-20-017725.pdf
0001140361-20-017725.rtf
0001140361-20-017725.xls
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Displaying 1 - 10 of 191 results

Data provided by Kaleidoscope.

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms